Table 3 One-sample MR estimates of psoriasis on the risk for site-specific cancers
Cancer | Sex | Case/total | OR (95% CI) | p value |
|---|---|---|---|---|
C04 malignant neoplasm of floor of mouth | Male and female | 83/458,587 | 1.17 (0.61, 2.23) | 0.648 |
Male | 61/209,587 | 1.86 (0.86, 4.04) | 0.117 | |
Female | 22/249,000 | 0.36 (0.11, 1.19) | 0.093 | |
C21 malignant neoplasm of anus and anal canal | Male and female | 369/458,587 | 1.38 (1.01, 1.87) | 0.041 |
Male | 124/209,587 | 0.97 (0.56, 1.68) | 0.909 | |
Female | 245/249,000 | 1.61 (1.12, 2.32) | 0.010 | |
C22 malignant neoplasm of liver and intrahepatic bile ducts | Male and female | 973/458,587 | 1.00 (0.83, 1.21) | 0.970 |
Male | 597/209,587 | 1.10 (0.85, 1.41) | 0.474 | |
Female | 376/249,000 | 0.88 (0.66, 1.18) | 0.406 | |
C26 malignant neoplasm of other and ill-defined digestive organs | Male and female | 340/458,587 | 1.19 (0.86, 1.63) | 0.303 |
Male | 195/209,587 | 1.10 (0.71, 1.71) | 0.688 | |
Female | 145/249,000 | 1.30 (0.81, 2.09) | 0.276 | |
C34 malignant neoplasm of bronchus and lung | Male and female | 5228/458,587 | 1.12 (1.03, 1.21) | 0.008 |
Male | 2690/209,587 | 1.17 (1.04, 1.32) | 0.009 | |
Female | 2538/249,000 | 1.07 (0.95, 1.19) | 0.278 | |
C44 other malignant neoplasms of skin | Male and female | 23072/458,587 | 1.04 (0.99, 1.08) | 0.092 |
Male | 12476/209,587 | 1.00 (0.95, 1.06) | 0.941 | |
Female | 10596/249,000 | 1.07 (1.01, 1.14) | 0.017 | |
C45 mesothelioma | Male and female | 496/458,587 | 0.92 (0.71, 1.21) | 0.578 |
Male | 399/209,587 | 0.84 (0.62, 1.14) | 0.267 | |
Female | 97/249,000 | 1.33 (0.75, 2.37) | 0.339 | |
C50 malignant neoplasm of breast | Male and female | 16276/458,587 | 1.06 (1.01, 1.12) | 0.012 |
Male | 132/209,587 | 0.79 (0.46, 1.36) | 0.402 | |
female | 16144/249,000 | 1.06 (1.02, 1.11) | 0.010 | |
C60 malignant neoplasm of penis | Male and female | NA | NA | NA |
Male | 114/209,587 | 0.61 (0.34,1.08) | 0.090 | |
Female | NA | NA | NA | |
C64 malignant neoplasm of kidney, except renal pelvis | Male and female | 2102/458,587 | 1.25 (1.09, 1.42) | 0.001 |
Male | 1348/209,587 | 1.34 (1.13, 1.58) | 0.001 | |
Female | 754/249,000 | 1.11 (0.91, 1.37) | 0.312 | |
C67 malignant neoplasm of bladder | Male and female | 4092/458,587 | 1.00 (0.91, 1.09) | 0.954 |
Male | 3068/209,587 | 0.98 (0.88, 1.10) | 0.791 | |
Female | 1024/249,000 | 1.03 (0.86, 1.24) | 0.735 | |
C77 secondary and unspecified malignant neoplasm of lymph nodes | Male and female | 11433/458,587 | 1.04 (0.98, 1.10) | 0.182 |
Male | 4587/209,587 | 1.06 (0.96, 1.16) | 0.257 | |
Female | 6846/249,000 | 1.03 (0.96, 1.10) | 0.432 | |
C78 secondary malignant neoplasm of respiratory and digestive organs | Male and female | 11621/458,587 | 1.05 (0.99, 1.11) | 0.086 |
Male | 5442/209,587 | 1.10 (1.01, 1.20) | 0.028 | |
Female | 6179/249,000 | 1.01 (0.94, 1.09) | 0.777 | |
C79 secondary malignant neoplasm of other sites | Male and female | 9300/458,587 | 1.10 (1.03, 1.17) | 0.004 |
Male | 4807/209,587 | 1.08 (0.98, 1.18) | 0.114 | |
Female | 4493/249,000 | 1.12 (1.02, 1.22) | 0.012 | |
C82 follicular [nodular] non-Hodgkin’s lymphoma | Male and female | 793/458,587 | 1.32 (1.07, 1.64) | 0.009 |
Male | 379/209,587 | 1.14 (0.83, 1.57) | 0.412 | |
Female | 414/249,000 | 1.50 (1.13, 1.98) | 0.005 | |
C97 malignant neoplasms of primary multiple sites | Male and female | 1335/458,587 | 1.02 (0.87, 1.20) | 0.805 |
Male | 786/209,587 | 1.02 (0.82, 1.27) | 0.870 | |
Female | 549/249,000 | 1.03 (0.80, 1.31) | 0.845 |
